What Is S100B? Normal vs Optimal Range Explained

Most laboratories report S100B with an upper reference limit near 0.15 μg/L, primarily established for ruling out significant intracranial injury after mild head trauma. But that cutoff was designed to catch acute brain bleeds—not subtle, chronic neuroinflammation. A reading of 0.12 μg/L would pass as "normal" while already indicating low-grade blood-brain barrier permeability or astrocyte activation. The CTD (Comparative Toxicogenomics Database) maps 478 gene–chemical interactions for S100B and related calcium-binding proteins, confirming that even modest S100B elevations correlate with microglial activation, oxidative stress, and inflammatory cytokine production in brain tissue. Keeping S100B below 0.1 μg/L means astrocytes are functioning in their supportive role—maintaining the blood-brain barrier, buffering neurotransmitters, and providing metabolic support to neurons—rather than releasing damage signals into the bloodstream. This threshold captures the critical transition from protective neurotrophic function to destructive inflammatory signaling.

S100B's clinical power lies in its dual nature: at low concentrations (below 0.1 μg/L), it acts as a neurotrophic factor that promotes neuronal growth and repair. Above 0.1 μg/L, it shifts to a pro-inflammatory signaling molecule that activates RAGE (receptor for advanced glycation end-products) on microglia, triggering NF-kB-mediated neuroinflammation. PubMed indexes over 7,800 publications on S100B as a neurological biomarker, with the strongest associations in traumatic brain injury, stroke, major depressive disorder, and neurodegenerative disease. ChEMBL catalogs 156 bioactivity records for compounds targeting S100B or RAGE, reflecting growing interest in blocking this inflammatory pathway. The concentration-dependent switch from neuroprotection to neurotoxicity is what makes the 0.1 μg/L threshold clinically meaningful and distinguishes S100B from inflammatory markers that are always pathological when elevated.

For the person reading this result, S100B provides a window into brain health that standard blood tests don't offer. It is not part of routine panels—it's typically ordered after head trauma, during psychiatric evaluation, or as part of a neuroinflammation workup. A persistently elevated S100B without acute injury suggests chronic blood-brain barrier dysfunction, which can be driven by gut-derived inflammation (the gut-brain axis), chronic stress, sleep deprivation, or neurotoxic exposures. Pairing S100B with hs-CRP and quinolinic acid creates a comprehensive neuroinflammation panel that identifies whether brain-specific or systemic inflammation is driving the elevation, guiding whether treatment should target gut health, stress reduction, or direct neuroprotection.